Cellectis (CLLS) Misses Q3 EPS by 16c

Cellectis (NASDAQ: CLLS) reported Q3 EPS of ($0.58), $0.16 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $3.58 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• KT&G approves KRW 360 billion share buyback and retirement plan
• AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c